These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36300303)

  • 1. Genistein improves renal disease in a mouse model of nephropathic cystinosis: a comparison study with cysteamine.
    De Leo E; Taranta A; Raso R; Polishchuk E; D'Oria V; Pezzullo M; Goffredo BM; Cairoli S; Bellomo F; Battafarano G; Camassei FD; Del Fattore A; Polishchuk R; Emma F; Rega LR
    Hum Mol Genet; 2023 Mar; 32(7):1090-1101. PubMed ID: 36300303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystinosin-deficient rats recapitulate the phenotype of nephropathic cystinosis.
    Hollywood JA; Kallingappa PK; Cheung PY; Martis RM; Sreebhavan S; 'Atiola RD; Chatterjee A; Buckels EJ; Matthews BG; Lewis PM; Davidson AJ
    Am J Physiol Renal Physiol; 2022 Aug; 323(2):F156-F170. PubMed ID: 35695380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Human Induced Pluripotent Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition Combination Therapy for Cystinosis.
    Hollywood JA; Przepiorski A; D'Souza RF; Sreebhavan S; Wolvetang EJ; Harrison PT; Davidson AJ; Holm TM
    J Am Soc Nephrol; 2020 May; 31(5):962-982. PubMed ID: 32198276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of long-term cysteamine treatment in patients with cystinosis.
    Ariceta G; Giordano V; Santos F
    Pediatr Nephrol; 2019 Apr; 34(4):571-578. PubMed ID: 29260317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-Based Phenotypic Drug Screening Identifies Luteolin as Candidate Therapeutic for Nephropathic Cystinosis.
    De Leo E; Elmonem MA; Berlingerio SP; Berquez M; Festa BP; Raso R; Bellomo F; Starborg T; Janssen MJ; Abbaszadeh Z; Cairoli S; Goffredo BM; Masereeuw R; Devuyst O; Lowe M; Levtchenko E; Luciani A; Emma F; Rega LR
    J Am Soc Nephrol; 2020 Jul; 31(7):1522-1537. PubMed ID: 32503896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of NACA and diNACA in human cystinosis fibroblast cell cultures as potential treatments for cystinosis.
    Hector E; Cairns D; Michael Wall G
    Orphanet J Rare Dis; 2022 Jun; 17(1):231. PubMed ID: 35710564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parenchymal organ cystine depletion with long-term cysteamine therapy.
    Gahl WA; Charnas L; Markello TC; Bernardini I; Ishak KG; Dalakas MC
    Biochem Med Metab Biol; 1992 Dec; 48(3):275-85. PubMed ID: 1476793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of infantile nephropathic cystinosis depends on early intervention, not genotype: A multicenter sibling cohort study.
    Veys K; Zadora W; Hohenfellner K; Bockenhauer D; Janssen MCH; Niaudet P; Servais A; Topaloglu R; Besouw M; Novo R; Haffner D; Kanzelmeyer N; Pape L; Wühl E; Harms E; Awan A; Sikora P; Ariceta G; van den Heuvel B; Levtchenko E
    J Inherit Metab Dis; 2023 Jan; 46(1):43-54. PubMed ID: 36117148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults.
    Brodin-Sartorius A; Tête MJ; Niaudet P; Antignac C; Guest G; Ottolenghi C; Charbit M; Moyse D; Legendre C; Lesavre P; Cochat P; Servais A
    Kidney Int; 2012 Jan; 81(2):179-89. PubMed ID: 21900880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatment of nephropathic cystinosis with cysteamine.
    Kleta R; Gahl WA
    Expert Opin Pharmacother; 2004 Nov; 5(11):2255-62. PubMed ID: 15500372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephropathic cystinosis: an update on genetic conditioning.
    Topaloglu R
    Pediatr Nephrol; 2021 Jun; 36(6):1347-1352. PubMed ID: 32564281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis.
    Emma F; Hoff WV; Hohenfellner K; Topaloglu R; Greco M; Ariceta G; Bettini C; Bockenhauer D; Veys K; Pape L; Hulton S; Collin S; Ozaltin F; Servais A; Deschênes G; Novo R; Bertholet-Thomas A; Oh J; Cornelissen E; Janssen M; Haffner D; Ravà L; Antignac C; Devuyst O; Niaudet P; Levtchenko E
    Kidney Int; 2021 Nov; 100(5):1112-1123. PubMed ID: 34237326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone Disease in Nephropathic Cystinosis: Beyond Renal Osteodystrophy.
    Machuca-Gayet I; Quinaux T; Bertholet-Thomas A; Gaillard S; Claramunt-Taberner D; Acquaviva-Bourdain C; Bacchetta J
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32354056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTNS mRNA molecular analysis revealed a novel mutation in a child with infantile nephropathic cystinosis: a case report.
    Papizh S; Serzhanova V; Filatova A; Skoblov M; Tabakov V; van den Heuvel L; Levtchenko E; Prikhodina L
    BMC Nephrol; 2019 Oct; 20(1):400. PubMed ID: 31672123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.
    Gahl WA; Kuehl EM; Iwata F; Lindblad A; Kaiser-Kupfer MI
    Mol Genet Metab; 2000; 71(1-2):100-20. PubMed ID: 11001803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.
    Bouazza N; Tréluyer JM; Ottolenghi C; Urien S; Deschenes G; Ricquier D; Niaudet P; Chadefaux-Vekemans B
    Orphanet J Rare Dis; 2011 Dec; 6():86. PubMed ID: 22195601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection of Cystinotic Mice by Kidney-Specific Megalin Ablation Supports an Endocytosis-Based Mechanism for Nephropathic Cystinosis Progression.
    Janssens V; Gaide Chevronnay HP; Marie S; Vincent MF; Van Der Smissen P; Nevo N; Vainio S; Nielsen R; Christensen EI; Jouret F; Antignac C; Pierreux CE; Courtoy PJ
    J Am Soc Nephrol; 2019 Nov; 30(11):2177-2190. PubMed ID: 31548351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NIH conference. Cystinosis: progress in a prototypic disease.
    Gahl WA; Thoene JG; Schneider JA; O'Regan S; Kaiser-Kupfer MI; Kuwabara T
    Ann Intern Med; 1988 Oct; 109(7):557-69. PubMed ID: 3048161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
    Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
    Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis.
    Hohenfellner K; Nießl C; Haffner D; Oh J; Okorn C; Palm K; Schlingmann KP; Wygoda S; Gahl WA
    Mol Genet Metab; 2022 Aug; 136(4):282-288. PubMed ID: 35843134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.